- Home
- LYB vs MDGL Comparison
LYB vs MDGL Comparison
Compare LYB & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LYB | MDGL |
|---|---|---|
| Founded | 1955 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.9B | 12.5B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | LYB | MDGL |
|---|---|---|
| Price | $47.79 | $553.26 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 14 |
| Target Price | $53.79 | ★ $580.77 |
| AVG Volume (30 Days) | ★ 5.0M | 301.8K |
| Earning Date | 01-30-2026 | 02-25-2026 |
| Dividend Yield | ★ 12.20% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $37,778,000,000.00 | $740,640,000.00 |
| Revenue This Year | N/A | $435.63 |
| Revenue Next Year | N/A | $52.56 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 6.37 | ★ 864.21 |
| 52 Week Low | $41.58 | $265.00 |
| 52 Week High | $79.39 | $615.00 |
Technical Indicators
Market Signals| Indicator | LYB | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 63.40 | 45.07 |
| Support Level | $44.31 | $532.45 |
| Resistance Level | $46.87 | $589.98 |
| Average True Range (ATR) | 1.40 | 21.40 |
| MACD | 0.49 | -5.96 |
| Stochastic Oscillator | 88.98 | 28.24 |
Price Performance
Historical ComparisonAbout LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.